Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 2
2001 1
2008 1
2009 1
2011 1
2012 1
2013 1
2014 1
2015 1
2016 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.
Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Bluhmki E, Patel S, Johansen OE, Woerle HJ. Rosenstock J, et al. Among authors: bluhmki e. Diab Vasc Dis Res. 2013 Jul;10(4):289-301. doi: 10.1177/1479164112475102. Epub 2013 Feb 28. Diab Vasc Dis Res. 2013. PMID: 23449634 Free article. Review.
Concerns have been raised from observational retrospective studies on the cardiovascular (CV) safety of SUs but there are few long-term data on CV outcomes from randomized controlled trials (RCTs) involving the use of this class of agents. ...To address the SU controversy, …
Concerns have been raised from observational retrospective studies on the cardiovascular (CV) safety of SUs but there are few long-term …
Sulfonylurea use before stroke does not influence outcome.
Favilla CG, Mullen MT, Ali M, Higgins P, Kasner SE; Virtual International Stroke Trials Archive (VISTA) Collaboration. Favilla CG, et al. Stroke. 2011 Mar;42(3):710-5. doi: 10.1161/STROKEAHA.110.599274. Epub 2011 Feb 17. Stroke. 2011. PMID: 21330623
CONCLUSIONS: Sulfonylurea use before stroke onset did not affect stroke severity or long-term functional outcome compared with other DM treatments. This finding casts doubt on the use of sulfonylureas for prophylactic neuroprotection. ...
CONCLUSIONS: Sulfonylurea use before stroke onset did not affect stroke severity or long-term functional outcome compared with other …
Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic?
Berger C, Fiorelli M, Steiner T, Schäbitz WR, Bozzao L, Bluhmki E, Hacke W, von Kummer R. Berger C, et al. Among authors: bluhmki e. Stroke. 2001 Jun;32(6):1330-5. doi: 10.1161/01.str.32.6.1330. Stroke. 2001. PMID: 11387495
BACKGROUND AND PURPOSE: The term symptomatic hemorrhage secondary to ischemic stroke implies a clear causal relationship between clinical deterioration and hemorrhagic transformation (HT) regardless of the type of HT. ...
BACKGROUND AND PURPOSE: The term symptomatic hemorrhage secondary to ischemic stroke implies a clear causal relationship between clin …
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).
Zinman B, Inzucchi SE, Lachin JM, Wanner C, Ferrari R, Fitchett D, Bluhmki E, Hantel S, Kempthorne-Rawson J, Newman J, Johansen OE, Woerle HJ, Broedl UC. Zinman B, et al. Among authors: bluhmki e. Cardiovasc Diabetol. 2014 Jun 19;13:102. doi: 10.1186/1475-2840-13-102. Cardiovasc Diabetol. 2014. PMID: 24943000 Free PMC article. Clinical Trial.
The aim of the ongoing EMPA-REG OUTCOME trial is to determine the long-term CV safety of empagliflozin, as well as investigating potential benefits on macro-/microvascular outcomes. ...
The aim of the ongoing EMPA-REG OUTCOME trial is to determine the long-term CV safety of empagliflozin, as well as investigating pote …
Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials.
Lees KR, Emberson J, Blackwell L, Bluhmki E, Davis SM, Donnan GA, Grotta JC, Kaste M, von Kummer R, Lansberg MG, Lindley RI, Lyden P, Murray GD, Sandercock PA, Toni D, Toyoda K, Wardlaw JM, Whiteley WN, Baigent C, Hacke W, Howard G; Stroke Thrombolysis Trialists’ Collaborators Group. Lees KR, et al. Among authors: bluhmki e. Stroke. 2016 Sep;47(9):2373-9. doi: 10.1161/STROKEAHA.116.013644. Epub 2016 Aug 9. Stroke. 2016. PMID: 27507856 Free PMC article. Clinical Trial.
Ordinal logistic regression models assessed treatment differences after adjustment for treatment delay, age, stroke severity, and relevant interaction term(s). RESULTS: Treatment with alteplase was beneficial for a delay in treatment extending to 4.5 hours after stroke ons …
Ordinal logistic regression models assessed treatment differences after adjustment for treatment delay, age, stroke severity, and relevant i …
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).
Marx N, Rosenstock J, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Espeland MA, Bluhmki E, Mattheus M, Ryckaert B, Patel S, Johansen OE, Woerle HJ. Marx N, et al. Among authors: bluhmki e. Diab Vasc Dis Res. 2015 May;12(3):164-74. doi: 10.1177/1479164115570301. Epub 2015 Mar 15. Diab Vasc Dis Res. 2015. PMID: 25780262 Free PMC article. Clinical Trial.
CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (NCT01243424) is an ongoing, randomized trial in subjects with early type 2 diabetes and increased cardiovascular risk or established complications that will determine the long-term cardiovas …
CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (NCT01243424) is an ongoing, randomized trial in subjects …
A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis.
Huskisson EC, Ghozlan R, Kurthen R, Degner FL, Bluhmki E. Huskisson EC, et al. Among authors: bluhmki e. Br J Rheumatol. 1996 Apr;35 Suppl 1:29-34. doi: 10.1093/rheumatology/35.suppl_1.29. Br J Rheumatol. 1996. PMID: 8630633
Meloxicam is a new non-steroidal anti-inflammatory drug (NSAID), which has a higher activity against cyclooxygenase-2 (COX-2) than against cyclooxygenase-1 (COX-1), with potentially high anti-inflammatory and analgesic action. This study was designed to assess the long-term …
Meloxicam is a new non-steroidal anti-inflammatory drug (NSAID), which has a higher activity against cyclooxygenase-2 (COX-2) than against c …
Primary end-point times, functional outcome and adverse event profile after acute ischaemic stroke.
Ali M, Sacco RL, Lees KR; VISTA investigators. Ali M, et al. Int J Stroke. 2009 Dec;4(6):432-42. doi: 10.1111/j.1747-4949.2009.00348.x. Int J Stroke. 2009. PMID: 19930052
CONCLUSIONS: We identified complications, which we deemed not to have occurred as a direct consequence of index stroke, but found that the absence of these events did not beneficially alter outcome at either short-term (30 days) or long-term (90 days) follow-up peri …
CONCLUSIONS: We identified complications, which we deemed not to have occurred as a direct consequence of index stroke, but found that the a …
14 results